Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1CNS 1

Conditions

Neuroblastoma 42Glioblastoma 38Brain Neoplasms 33Glioma 31Central Nervous System Neoplasms 27Gliosarcoma 22Astrocytoma 22Oligodendroglioma 16Medulloblastoma 13Neoplasms 12Rhabdomyosarcoma 7Osteosarcoma 7Recurrence 6Ependymoma 5Diffuse Intrinsic Pontine Glioma 5Sarcoma, Ewing 4Optic Nerve Glioma 4Ganglioneuroblastoma 4Familial ependymoma 4Breast Neoplasms 4Sarcoma 3Rhabdoid Tumor 3Pinealoma 3Pancreatic Neoplasms 3Neurologic Manifestations 3Neuroectodermal Tumors, Primitive, Peripheral 3Colonic Neoplasms 3Choroid Plexus Neoplasms 3Bone Neoplasms 3Wilms Tumor 2

Interventions

sodium thiosulfate 3Filgrastim 3Carboplatin 3etoposide phosphate 2Cyclophosphamide 2pegfilgrastim 1Vincristine 1Trastuzumab 1Temozolomide 1Rituximab 1Procarbazine 1Methotrexate 1Mannitol 1Lomustine 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Genetic Therapy 1Etoposide 1Cytarabine 1Cefixime 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × Irinotecan × CNS × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡